When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With ANIX Stock Today?
Anixa Biosciences Inc (ANIX) stock has risen 5.03% while the S&P 500 has fallen -0.07% as of 1:20 PM on Wednesday, Mar 20. ANIX has risen $0.18 from the previous closing price of $3.60 on volume of 349,697 shares. Over the past year the S&P 500 is up 30.96% while ANIX has fallen -4.30%. ANIX lost -$0.35 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Anixa Biosciences Inc click here.
More About Anixa Biosciences Inc
Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for early detection of solid tumours which is based on the body's immune response to the presence of a malignancy. The company is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs that genetically engineer patient's own immune cells to fight cancer.
Click Here to get the full Stock Report for Anixa Biosciences Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
